ACC: Coronary Artery Calcium Progression May Accelerate After Menopause
By Lori Solomon HealthDay Reporter
TUESDAY, April 2 -- Postmenopausal changes may accelerate coronary artery calcium (CAC) progression in women, according to a study presented at the annual meeting of the American College of Cardiology, held from April 6 to 8 in Atlanta.
Ella Ishaaya, M.D., from Harbor-UCLA Medical Center in Torrance, California, and colleagues compared CAC progression between postmenopausal women and age-matched men with equivalent statin therapy and coronary artery disease risk factors to determine if postmenopausal changes contribute to faster CAC progression. The analysis included 579 postmenopausal women on statin therapy who underwent baseline and follow-up CAC scans at least one year apart, as well as male patients, matched (1:1) for age, race, statin use, hypertension, and diabetes mellitus.
The researchers found that for a baseline CAC level of 1 to 99, women had significantly higher CAC progression versus men (8 versus 4 points). Annualized median CAC change for a baseline CAC of 100 to 399 was 31 versus 16 points for women versus men. When CAC was >400, there was no significant difference observed in annualized progression by gender.
"This is a unique study cohort of only postmenopausal statin users that signals that postmenopausal women may have risk of heart disease that is on par with males," Ishaaya said in a statement. "Women are underscreened and undertreated, especially postmenopausal women, who have a barrage of new risk factors that many are not aware of. This study raises awareness of what those risk factors are and opens the door to indicating the importance of increased screening for coronary artery calcium."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted April 2024
Read this next
Fezolinetant Safe, Effective for Moderate-to-Severe Menopause Hot Flashes
MONDAY, May 20, 2024 -- Fezolinetant is safe and effective for moderate-to-severe vasomotor symptoms (VMS), according to a study presented at the annual European Congress of...
Risk for Depressive Symptoms Increased for Perimenopausal Women
THURSDAY, May 9, 2024 -- Perimenopausal women have an increased risk for depressive symptoms and diagnoses, according to a review published in the July 15 issue of the Journal of...
Surgical Premature Menopause Tied to Risk for Muscle Disorders
TUESDAY, May 7, 2024 -- Women experiencing surgical premature menopause (PM) have a higher likelihood of developing musculoskeletal disorders, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.